AnGes, Inc. (4563.T)
JPY 78.0
(5.41%)
JPY 78.0
(5.41%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -3.06 Billion JPY | -4.97% |
| 2022 | -2.92 Billion JPY | -39425.03% |
| 2021 | 7.42 Million JPY | -56.26% |
| 2020 | 16.97 Million JPY | -92.91% |
| 2019 | 239.56 Million JPY | -43.22% |
| 2018 | 421.87 Million JPY | 125.44% |
| 2017 | 187.13 Million JPY | -44.92% |
| 2016 | 339.75 Million JPY | 35.66% |
| 2015 | 250.45 Million JPY | -67.0% |
| 2014 | 758.92 Million JPY | 110.76% |
| 2013 | 360.08 Million JPY | 14.22% |
| 2012 | 315.25 Million JPY | 124.6% |
| 2011 | -1.28 Billion JPY | -3.69% |
| 2010 | -1.23 Billion JPY | 32.56% |
| 2009 | -1.83 Billion JPY | 8.84% |
| 2008 | -2 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -742.28 Million JPY | 7.54% |
| 2024 Q2 | -778.69 Million JPY | 110.24% |
| 2023 Q1 | -8.55 Million JPY | 98.9% |
| 2023 Q4 | -802.81 Million JPY | -4256.84% |
| 2023 Q2 | 1.44 Million JPY | 116.88% |
| 2023 FY | -3.06 Billion JPY | -4.97% |
| 2023 Q3 | 19.31 Million JPY | 1238.39% |
| 2022 Q2 | -3.79 Million JPY | -261.62% |
| 2022 Q4 | -775.88 Million JPY | -3320.42% |
| 2022 Q1 | -1.05 Million JPY | -145.71% |
| 2022 FY | -2.92 Billion JPY | -39425.03% |
| 2022 Q3 | -22.68 Million JPY | -497.42% |
| 2021 Q2 | 4.63 Million JPY | -0.06% |
| 2021 Q4 | 2.29 Million JPY | 155.43% |
| 2021 FY | 7.42 Million JPY | -56.26% |
| 2021 Q3 | -4.14 Million JPY | -189.41% |
| 2021 Q1 | 4.63 Million JPY | -1.72% |
| 2020 Q4 | 4.71 Million JPY | 2.05% |
| 2020 Q2 | 5.35 Million JPY | 135.16% |
| 2020 Q1 | 2.27 Million JPY | 376.57% |
| 2020 Q3 | 4.62 Million JPY | -13.68% |
| 2020 FY | 16.97 Million JPY | -92.91% |
| 2019 Q1 | 39.58 Million JPY | -85.93% |
| 2019 FY | 239.56 Million JPY | -43.22% |
| 2019 Q3 | 150.24 Million JPY | 205.03% |
| 2019 Q2 | 49.25 Million JPY | 24.43% |
| 2019 Q4 | 478 Thousand JPY | -99.68% |
| 2018 Q2 | 52.05 Million JPY | 38.37% |
| 2018 Q1 | 37.62 Million JPY | -32.9% |
| 2018 Q3 | 50.93 Million JPY | -2.17% |
| 2018 FY | 421.87 Million JPY | 125.44% |
| 2018 Q4 | 281.26 Million JPY | 452.26% |
| 2017 Q2 | 44.16 Million JPY | 3.13% |
| 2017 FY | 187.13 Million JPY | -44.92% |
| 2017 Q4 | 56.06 Million JPY | 27.17% |
| 2017 Q3 | 44.08 Million JPY | -0.17% |
| 2017 Q1 | 42.82 Million JPY | -79.88% |
| 2016 Q4 | 212.82 Million JPY | 397.39% |
| 2016 Q3 | 42.78 Million JPY | -0.91% |
| 2016 Q2 | 43.18 Million JPY | 5.41% |
| 2016 Q1 | 40.96 Million JPY | -29.7% |
| 2016 FY | 339.75 Million JPY | 35.66% |
| 2015 Q2 | 107.76 Million JPY | 136.16% |
| 2015 FY | 250.45 Million JPY | -67.0% |
| 2015 Q1 | 45.63 Million JPY | -92.21% |
| 2015 Q3 | 38.78 Million JPY | -64.0% |
| 2015 Q4 | 58.27 Million JPY | 50.23% |
| 2014 Q1 | 55.44 Million JPY | -4.89% |
| 2014 FY | 758.92 Million JPY | 110.76% |
| 2014 Q2 | 51.43 Million JPY | -7.24% |
| 2014 Q4 | 585.64 Million JPY | 781.9% |
| 2014 Q3 | 66.4 Million JPY | 29.11% |
| 2013 Q4 | 58.29 Million JPY | 43.51% |
| 2013 FY | 360.08 Million JPY | 14.22% |
| 2013 Q3 | 40.61 Million JPY | -74.45% |
| 2013 Q2 | 158.97 Million JPY | 55.56% |
| 2013 Q1 | 102.19 Million JPY | -89.72% |
| 2012 Q2 | -221.62 Million JPY | 19.1% |
| 2012 Q4 | 993.74 Million JPY | 643.26% |
| 2012 Q3 | -182.92 Million JPY | 17.46% |
| 2012 FY | 315.25 Million JPY | 124.6% |
| 2012 Q1 | -273.93 Million JPY | 23.0% |
| 2011 Q4 | -355.75 Million JPY | -51.17% |
| 2011 Q1 | -439.79 Million JPY | -23.99% |
| 2011 Q2 | -250.49 Million JPY | 43.04% |
| 2011 Q3 | -235.33 Million JPY | 6.05% |
| 2011 FY | -1.28 Billion JPY | -3.69% |
| 2010 Q1 | -318.75 Million JPY | -15.84% |
| 2010 Q2 | -287.09 Million JPY | 9.93% |
| 2010 Q4 | -354.7 Million JPY | -28.9% |
| 2010 Q3 | -275.17 Million JPY | 4.15% |
| 2010 FY | -1.23 Billion JPY | 32.56% |
| 2009 Q3 | -478.28 Million JPY | 0.65% |
| 2009 FY | -1.83 Billion JPY | 8.84% |
| 2009 Q2 | -481.42 Million JPY | 19.41% |
| 2009 Q4 | -275.17 Million JPY | 42.47% |
| 2009 Q1 | -597.34 Million JPY | 0.0% |
| 2008 FY | -2 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 262.935% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 3917.009% |
| GNI Group Ltd. | 22.43 Billion JPY | 113.665% |
| Linical Co., Ltd. | 3.77 Billion JPY | 181.129% |
| Trans Genic Inc. | 2.24 Billion JPY | 236.28% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 3219.821% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 223.482% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 337.139% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | -1624.804% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 131.719% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 692.563% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 2862.615% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 311.312% |
| CanBas Co., Ltd. | -984 Million JPY | -211.513% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 882.564% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 285.085% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 869.023% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 394.914% |
| PeptiDream Inc. | 17.21 Billion JPY | 117.802% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | 10115.641% |
| Ribomic Inc. | -10.5 Million JPY | -29087.65% |
| SanBio Company Limited | -14.5 Million JPY | -21034.08% |
| Healios K.K. | 108 Million JPY | 2938.229% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | -898811.144% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | -5091.354% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | -202630.622% |
| StemRIM | -44.34 Million JPY | -6811.739% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 196.241% |
| FunPep Company Limited | -680.28 Million JPY | -350.587% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 4526.407% |
| Stella Pharma Corporation | 217.29 Million JPY | 1510.637% |
| TMS Co., Ltd. | -6.95 Million JPY | -44004.849% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 1074.465% |
| Cuorips Inc. | 9.63 Million JPY | 31927.297% |
| K Pharma,Inc. | 910 Million JPY | 436.845% |
| Takara Bio Inc. | 25.45 Billion JPY | 112.041% |
| ReproCELL Incorporated | 1.1 Billion JPY | 377.471% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 356.497% |
| StemCell Institute Inc. | 1.57 Billion JPY | 294.512% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 283.904% |
| CellSeed Inc. | 107.15 Million JPY | 2960.61% |